What are the recommended treatments for each stage of non‑small cell lung cancer according to the latest IASLC staging?

Treatment of Non-Small Cell Lung Cancer by IASLC Stage

For stage I-II NSCLC, surgery with anatomical resection (lobectomy) is the primary treatment, followed by adjuvant cisplatin-based chemotherapy for stage II and select stage IB patients; for stage III disease, concurrent platinum-based chemoradiotherapy is the standard approach for unresectable cases, while resectable stage III requires neoadjuvant systemic therapy followed by surgery.

Stage I NSCLC

Surgical Candidates

• Perform anatomical resection (lobectomy) over wedge or segmental resection 1
• Lymph node dissection must conform to IASLC staging specifications 1
• Either open thoracotomy or VATS is acceptable based on surgeon expertise 1

Non-Surgical Candidates

• Stereotactic ablative radiotherapy (SABR) is the treatment of choice 1
• Dose should achieve biologically equivalent tumor dose ≥100 Gy prescribed to the encompassing isodose 1
• For tumors >5 cm or central location, use conventional daily or accelerated radiotherapy schedules 1

Adjuvant Therapy

• No routine adjuvant chemotherapy for most stage I patients 1
• Consider adjuvant therapy for stage IB with primary tumor >4 cm, though evidence is weaker 1
• Postoperative radiotherapy is NOT recommended for completely resected early-stage disease 1

---

Stage II NSCLC

Primary Treatment

• Surgery with anatomical resection (lobectomy) 1
• Lymph node dissection per IASLC specifications 1

Adjuvant Therapy

• Adjuvant cisplatin-based chemotherapy is mandatory 1
• Use two-drug combination with cisplatin, cumulative dose up to 300 mg/m² over 3-4 cycles 1
• Cisplatin-vinorelbine is the most extensively studied regimen 1
• Survival benefit at 5 years: 11.6% for stage II 2

Important Caveats

• Do NOT guide adjuvant therapy choice by ERCC1 or mutation testing 1
• Do NOT use targeted agents in adjuvant setting 1
• Postoperative radiotherapy is NOT recommended for completely resected disease 1

---

Stage III NSCLC

Stage III requires careful distinction between resectable and unresectable disease, with performance status being the critical determinant.

Resectable Stage III (Including N2 Disease)

For patients planned for multimodality approach with surgery:

Neoadjuvant Therapy (Preferred)

• Administer neoadjuvant chemotherapy or concurrent chemoradiotherapy before surgery 3
• For N2 disease specifically: neoadjuvant chemotherapy OR neoadjuvant concurrent chemoradiotherapy 3
• For superior sulcus tumors: neoadjuvant concurrent chemoradiotherapy is mandatory 3

Critical Point: Neoadjuvant therapy followed by surgery is neither clearly superior nor inferior to definitive chemoradiation, but weak data suggest benefit if only lobectomy is needed in centers with low perioperative mortality 4

Surgical Approach

• Surgery preferably considered when complete resection by lobectomy is expected 1
• More complex resections after induction should only be performed in experienced centers 1

Adjuvant Therapy (If No Neoadjuvant Therapy Given)

• Platinum-based chemotherapy is mandatory for resected stage III without prior neoadjuvant therapy 3
• For EGFR exon 19 deletion or exon 21 L858R mutation: offer adjuvant osimertinib after platinum-based chemotherapy 3

Postoperative Radiotherapy

• NOT routinely recommended for completely resected N2 disease without extracapsular extension after chemotherapy 3
• May be considered in select N2 patients, delivered after chemotherapy 1
• Indicated only after incomplete surgery 1

---

Unresectable Stage III (N2,3 Disease)

Performance Status 0-1 with Minimal Weight Loss:

Primary Treatment

• Concurrent platinum-based chemoradiotherapy is the standard (Grade 1A) 4
• Concurrent is superior to sequential chemoradiotherapy (Grade 1A) 4
• Radiotherapy dose: 60-66 Gy 4
• Do NOT escalate radiation dose outside clinical trials 4

Chemotherapy Regimens

• Cisplatin-based doublet is preferred 1, 3
• Recommended combinations:
  • Cisplatin plus etoposide 3
  • Cisplatin plus vinorelbine 1, 3
  • Carboplatin plus paclitaxel (acceptable alternative) 3
  • Cisplatin plus pemetrexed (non-squamous only) 3
• Cisplatin dose: approximately 80 mg/m² per cycle 1
• Number of cycles: 2-4 1

Important: Carboplatin-based regimens generally show inferior outcomes but may be chosen based on comorbidities 1. Carboplatin may substitute for cisplatin in patients with contraindications 3.

Consolidation Therapy

• Durvalumab for up to 12 months after concurrent chemoradiation without disease progression (Grade 1A) 3
• Do NOT use consolidation chemotherapy or EGFR-TKI after concurrent chemoradiotherapy (Grade 1A) 1

Induction Therapy

• Cannot recommend for or against induction chemotherapy before concurrent chemoradiotherapy—refer to clinical trials 4
• Carboplatin-based induction is NOT recommended 1

---

Performance Status 2 or Substantial Weight Loss (>10%):

• Concurrent chemoradiotherapy may be offered but with careful consideration of risks versus benefits (Grade 2C) 4
• Patient preferences should play significant role in decision-making 4

---

Patients Unfit for Concurrent Chemoradiotherapy:

• Sequential chemotherapy followed by radiotherapy is preferred over radiotherapy alone 3
• Use platinum-based two-drug combination, 2-4 cycles 1
• Radiotherapy delivered in short overall treatment time is recommended 1

---

Patients Receiving Radiotherapy Alone:

• Consider radiation dose escalation and modest hypofractionation (2.15-4 Gy per fraction) 3
• This is a weak recommendation with low-quality evidence 3

---

Special Considerations for Stage III

Prophylactic Cranial Irradiation (PCI):

• Do NOT give PCI even after complete response to concurrent chemoradiotherapy (Grade 2C) 4, 1, 4
• PCI delays CNS metastases but does not improve survival 4

Neoadjuvant Therapy Followed by Surgery:

• NOT routinely recommended for infiltrative stage III (N2,3) disease with performance status 0-1 (Grade 1C) 4
• Exception: May consider for resectable locally advanced NSCLC, especially single nodal station N2 disease, where both definitive chemoradiotherapy and induction therapy followed by surgery are options 1

---

Key Algorithmic Decision Points

1. Determine resectability based on anatomic extent and patient fitness
2. Assess performance status: 0-1 versus 2 versus >2
3. Evaluate weight loss: <10% versus >10%
4. For resectable disease: Choose neoadjuvant therapy → surgery → adjuvant therapy if needed
5. For unresectable disease with PS 0-1: Concurrent chemoradiotherapy → durvalumab consolidation
6. For unresectable disease with PS 2 or poor fitness: Sequential therapy or radiotherapy alone

---

Common Pitfalls to Avoid

• Do not use radiotherapy alone for stage III with good performance status—this is inferior to combined modality 4
• Do not routinely perform postoperative radiotherapy after complete resection—it improves local control but not survival 4
• Do not use consolidation chemotherapy or targeted therapy after definitive chemoradiation for stage III 1
• Do not escalate radiation dose beyond 60-66 Gy outside clinical trials 4
• Do not forget to refer all stage IB-III patients to medical oncology for adjuvant therapy discussion—surgeon referral is the greatest driver of completion 2